Ongoing developments in our research laboratories

• Class/structure: Proprietary/experimental peptide blend (limited public sequence data).
• Mechanism: Reported neuromodulatory and metabolic signaling effects; mechanisms not well characterized in peer-reviewed literature.
• Context: Early/preclinical or anecdotal research use.

• Structure: C-terminal fragment of human growth hormone.
• Mechanism: Activates lipolysis and inhibits lipogenesis, likely via β3-adrenergic pathways and hormone-sensitive lipase, without classical GH receptor–mediated anabolic effects.
• Context: Studied for obesity/metabolic modulation.

• Structure: 11-aa peptide derived from erythropoietin helix B.
• Mechanism: Selectively activates the EPOR/CD131 “tissue-protective receptor,” driving anti-inflammatory and cytoprotective signaling (JAK2/STAT, PI3K/Akt).
• Context: Neuropathy, ischemia-reperfusion injury.

• Structure: 15-aa gastric pentadecapeptide.
• Mechanism: Promotes angiogenesis (VEGF modulation), nitric oxide signaling, and fibroblast migration; influences FAK-paxillin pathways.
• Context: Tendon/ligament and GI healing models.

• Structure: Long-acting amylin analogue.
• Mechanism: Agonism at amylin/calcitonin receptors → delayed gastric emptying, increased satiety, central appetite regulation.
• Context: Metabolic disease/weight regulation.

• Structure: Short peptide complex (sequence not standardized publicly).
• Mechanism: Proposed gene expression modulation in cardiomyocytes; limited validated mechanistic data.
• Context: Niche/low-evidence cardiotropic claims.

• Structure: GHRH(1–29) analogue.
• Mechanism: Binds GHRH receptor → pulsatile GH release via cAMP/PKA signaling.
• Context: Short half-life GH secretagogue.

• Structure: GHRH analogue with Drug Affinity Complex (albumin binding).
• Mechanism: Prolonged GHRH receptor activation → sustained GH/IGF-1 elevation.
• Context: Long-acting GH axis modulation.

• Structure: Nonapeptide.
• Mechanism: Proposed modulation of thalamic/hypothalamic circuits and neuroendocrine axes; inconsistent reproducibility.
• Context: Sleep and stress research.

• Structure: Tetrapeptide Ala-Glu-Asp-Gly.
• Mechanism: Reported telomerase activation, antioxidant effects, and circadian regulation via pineal signaling.
• Context: Aging/gerontology models.

• Structure: D-retro-inverso peptide targeting FOXO4–p53 interaction.
• Mechanism: Disrupts FOXO4–p53 binding in senescent cells → p53 nuclear exclusion/apoptosis of senescent cells (senolytic).
• Context: Aging/senescence clearance studies.

• Structure: Tripeptide Gly-His-Lys chelating Cu²⁺.
• Mechanism: Regulates gene expression for ECM remodeling, collagen synthesis, angiogenesis; anti-inflammatory.
• Context: Skin repair, wound healing.

• Structure: Synthetic hexapeptide (GHRP class).
• Mechanism: Ghrelin receptor (GHS-R1a) agonist → GH release; also cardioprotective signaling (MAPK/PI3K).
• Context: GH secretagogue research.

• Structure: IGF-1 analogue with Arg³ substitution and 13-aa extension.
• Mechanism: Reduced IGFBP binding → increased bioavailability; activates IGF-1R → PI3K/Akt and MAPK pathways (anabolic, mitogenic).
• Context: Cell growth/proliferation models.

• Structure: Decapeptide fragment of kisspeptin.
• Mechanism: Agonist at KISS1R → stimulates GnRH neurons → LH/FSH release.
• Context: Reproductive endocrinology.

• Structure: Tripeptide derived from α-MSH.
• Mechanism: Anti-inflammatory via NF-κB inhibition and cytokine downregulation.
• Context: Dermatologic and GI inflammation models.

• Structure: Human cathelicidin antimicrobial peptide (37 aa).
• Mechanism: Disrupts microbial membranes; immunomodulatory (chemotaxis, cytokines).
• Context: Host defense, wound healing.

• Structure: α-MSH analogue.
• Mechanism: MC1R agonism → increased eumelanin synthesis.
• Context: Pigmentation disorders, photoprotection.

• Structure: 16-aa peptide encoded by mitochondrial 12S rRNA.
• Mechanism: Regulates metabolic homeostasis via AMPK activation and nuclear gene expression under stress.
• Context: Metabolism/aging.

• Structure: Modified Selank (heptapeptide) with N-acetylation and C-terminal amidation.
• Mechanism: Modulates GABAergic signaling and BDNF; increased stability vs. parent peptide.
• Context: Anxiolytic/nootropic research.

• Structure: Modified Semax (ACTH 4–10 analogue) with acetylation/amidation.
• Mechanism: Enhances BDNF/TrkB signaling, dopaminergic modulation; neuroprotective.
• Context: Cognitive and ischemic models.

• Structure: Nicotinamide adenine dinucleotide with stabilizing buffers.
• Mechanism: Central redox cofactor; substrate for sirtuins and PARPs; supports mitochondrial function.
• Context: Cellular energetics/aging.

• Structure: Peptide derived from CNTF region.
• Mechanism: Enhances neurogenesis and synaptic plasticity; modulates GSK-3β and BDNF pathways.
• Context: Neurodegeneration models.

• Structure: Heptapeptide fragment of spadin (from sortilin/pro-BDNF pathway).
• Mechanism: TREK-1 potassium channel inhibition → antidepressant-like signaling.
• Context: Mood disorder research.

• Structure: Tripeptide Glu-Asp-Arg.
• Mechanism: Proposed epigenetic/gene expression modulation in neurons; limited high-quality data.
• Context: Neuroprotective claims.

• Structure: Cyclic heptapeptide melanocortin analogue.
• Mechanism: MC3R/MC4R agonism in CNS → modulation of sexual arousal pathways.
• Context: Neuroendocrine/sexual function.

• Structure: Heptapeptide (Tuftsin analogue).
• Mechanism: GABAergic modulation, enkephalinase inhibition, BDNF effects; anxiolytic profile in studies.
• Context: Stress/anxiety research.

• Structure: ACTH(4–10) analogue.
• Mechanism: Increases BDNF, modulates monoamines; neuroprotective in ischemia models.
• Context: Cognitive/neurologic research.

• Structure: GHRH(1–29).
• Mechanism: Stimulates pituitary GH release via GHRH receptor.
• Context: GH axis evaluation.

• Structure: Octapeptide derived from SNAP-25 sequence.
• Mechanism: Interferes with SNARE complex formation → reduced neurotransmitter release (cosmetic “anti-wrinkle” mechanism).
• Context: Topical/cosmeceutical studies.

• Structure: Mitochondria-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH₂).
• Mechanism: Binds cardiolipin → stabilizes electron transport chain, reduces ROS, improves ATP production.
• Context: Mitochondrial dysfunction, myopathy.

• Structure: Dual agonist peptide.
• Mechanism: GLP-1 and glucagon receptor co-agonism → energy expenditure, glycemic control, weight effects.
• Context: Metabolic disease.

• Structure: 43-aa actin-binding peptide.
• Mechanism: Sequesters G-actin, promotes cell migration, angiogenesis, and tissue repair.
• Context: Regeneration/wound healing.

• Structure: Short fragment of thymosin β4.
• Mechanism: Proposed to retain partial actin/repair signaling; reduced evidence vs. full peptide.
• Context: Experimental.

• Structure: Thymic peptide complex.
• Mechanism: Proposed immunomodulation (T-cell function); limited standardized data.
• Context: Low-evidence immune claims.

• Structure: 28-aa thymic peptide.
• Mechanism: Enhances T-cell maturation, dendritic cell function; modulates Toll-like receptor signaling.
• Context: Immunology/antiviral oncology adjunct research.

• Structure: Nonapeptide thymic hormone (zinc-dependent).
• Mechanism: Regulates T-cell differentiation and cytokine balance.
• Context: Immune function studies.

• Structure: Multi-agonist incretin peptide.
• Mechanism: Concurrent agonism at GLP-1, GIP, and glucagon receptors → integrated effects on insulin secretion, satiety, and energy expenditure.
• Context: Obesity/diabetes research.

Capture and analyze full experimental recordings, enhancing data accuracy for thorough research evaluations.

• Structure: 28-aa neuropeptide.
• Mechanism: VPAC1/VPAC2 receptor agonist → cAMP increase; vasodilation, bronchodilation, immunomodulation.
• Context: Neuroimmune and pulmonary research.

Structure: Multi-peptide formulation combining KPV tripeptide, copper-binding tripeptide (GHK-Cu), thymosin beta-4 fragment (TB-500), and a synthetic gastric-derived pentadecapeptide (BPC-157).

Mechanism: Synergistic action across anti-inflammatory, tissue remodeling, and regenerative pathways. Includes inhibition of pro-inflammatory cytokine signaling (KPV), enhancement of collagen synthesis and antioxidant activity (GHK-Cu), stimulation of cell migration and angiogenesis (TB-500), and modulation of growth factors and nitric oxide signaling to support cytoprotection and vascular repair (BPC-157).

Context: Investigational regenerative peptide blend used in research settings focused on inflammation control, musculoskeletal recovery, soft tissue repair, and gastrointestinal protection.

Formula: Premium 4-peptide blend: KPV | GHK-Cu | TB-500 | BPC-157 | Form: Blue lyophilized powder | Purity: ≥99% | Storage: 2-8°C

Structure: Combination of bioactive peptides (GHK-Cu tripeptide, TB-500 thymosin beta-4 fragment, and BPC-157 pentadecapeptide).

Mechanism: Synergistic action on tissue repair and regeneration pathways. GHK-Cu is associated with collagen synthesis and skin remodeling; TB-500 is linked to actin regulation and cellular migration; BPC-157 is associated with angiogenesis and modulation of inflammatory and healing responses.

Context: Research use in tissue repair, wound healing, and regenerative biology studies.

Formula:Premium 3-peptide blend: GHK-Cu | TB-500 | BPC-157 | Form: Blue lyophilized powder | Purity: ≥99% | Storage: 2-8°C

Structure: Combination of growth hormone secretagogue peptides (CJC-1295 without DAC and Ipamorelin).

Mechanism: Dual stimulation of growth hormone release via complementary pathways. CJC-1295 (no DAC) acts as a GHRH (growth hormone-releasing hormone) analog with short duration, increasing pulsatile GH secretion. Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist that stimulates GH release while minimizing prolactin and cortisol effects compared to older secretagogues.

Context: Research use in studies related to growth hormone dynamics, metabolic regulation, and body composition.

Formula: Premium 2-peptide blend: CJC-1295 (no DAC) | Ipamorelin | Form: White powder | Purity: ≥99% | Storage: 2-8°C

Description: A peptide blend of GHRP-2, Tesamorelin, Ipamorelin, and Mechano Growth Factor (MGF) offers a multifaceted approach to tissue regeneration, muscle growth, and metabolic health. GHRP-2, Tesamorelin, and Ipamorelin stimulate growth hormone release with complementary profiles, while MGF directly promotes muscle repair and regeneration. Together, the blend may enhance muscle growth, improve recovery, support metabolic function, and address age-related muscle decline, offering broad potential in regenerative medicine, sports science, and GH therapy research.

Formula: Premium 4-peptide blend: Tesamorelin | Ipamorelin | MGF | GHRP-2 | Form: White powder | Purity: ≥99% | Storage: 2-8°C

Descrition: A peptide blend of Tesamorelin, Ipamorelin, and Mechano Growth Factor (MGF) offers a comprehensive approach to muscle growth, tissue repair, and metabolic support. Tesamorelin and Ipamorelin stimulate growth hormone release with complementary profiles, while MGF directly promotes muscle regeneration and repair. Together, this combination may enhance muscle development, improve recovery, support metabolic health, and help counter age-related muscle decline, making it valuable in regenerative medicine and sports science.

Formula: Premium 3-peptide blend: Tesamorelin | MGF | Ipamorelin | Form: White powder | Purity: ≥99% | Storage: 2-8°C

Desciption: A peptide blend of Tesamorelin and Ipamorelin offers a synergistic approach to enhancing growth hormone (GH) release and supporting metabolic health. Tesamorelin reduces visceral fat, while Ipamorelin is a selective GH secretagogue with a strong safety profile. Together, they may help address GH deficiency-related conditions, including muscle wasting, obesity, and potentially cognitive health.

Formula: Premium 2-peptide blend: Tesamorelin | Ipamorelin | Form: White powder | Purity: ≥99% | Storage: 2-8°C

Description: BPC-157 (Body Protection Compound 157) is a synthetic peptide derived from a naturally occurring peptide in human gastric juice, known for its potential therapeutic effects. TB-500 (Thymosin Beta 4) is a naturally occurring peptide found in platelets and wound fluid that supports tissue repair, regeneration, and inflammation reduction by promoting actin polymerization.

Formula: Premium 2-peptide blend: BPC-157 | TB-500 (43 amino acid chain) | Form: White powder | Purity: ≥99% | Storage: 2-8°C